Explore
Validate
LearnPA5-56603
antibody from Invitrogen Antibodies
Targeting: FNDC1
bA243O10.1, dJ322A24.1, FNDC2, KIAA1866
ImmunocytochemistryAntibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Immunocytochemistry [1]
- Immunohistochemistry [1]
- Other assay [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-56603 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- FNDC1 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Recombinant full-length protein
- Description
- Immunogen sequence: ECYAEEDEFS GLETDTAVPT EEAYVIYDED YEFETSRPPT TTEPSTTATT PRVIPEEGAI SSFPEEEFDL AGRKRFVAPY VTYLNKDPSA PCSLTDALD
- Concentration
- 0.2 mg/mL
Submitted references The silencing of FNDC1 inhibits the tumorigenesis of breast cancer cells via modulation of the PI3K/Akt signaling pathway.
Yunwen C, Shanshan G, Zhifei B, Saijun C, Hua Y
Molecular medicine reports 2021 Jun;23(6)
Molecular medicine reports 2021 Jun;23(6)
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescent staining of FNDC1 in human cell line A-431 shows positivity in nucleus but excluded from the nucleoli. Samples were probed using a FNDC1 Polyclonal Antibody (Product # PA5-56603).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical staining of FNDC1 in human cerebral cortex tissue shows strong nuclear membranous positivity in neuronal cells. Samples were probed using a FNDC1 Polyclonal Antibody (Product # PA5-56603).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 2. The silencing of FNDC1 inhibits the tumorigenesis of BC. (A) Expression of FNDC1 in normal breast cell and BC cells were assayed by western blotting. (B) BC cells were transfected as indicated for 24 h, after which the protein levels of FNDC1 were measured by western blotting. (C) BC cells were transfected as indicated, after which the cell viability was measured by a Cell Counting kit-8 assay at different time points. (D) BC cells were transfected as indicated, after which a colony formation assay was performed. (E) BC cells were transfected as indicated, after which a wound healing assay was conducted to measure the migration ability. (F) BC cells were transfected as indicated, after which a Transwell assay was performed to measure the invasive ability. (G) BC cells were transfected as indicated for 24 h, after which the expression levels of the indicated proteins were measured by western blotting. The data are presented as the mean +- standard deviation. The experiments were performed at least three times. *P
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 3. The silencing of FNDC1 leads to inhibition of the PI3K/Akt signaling pathway. (A and B) BC cells were transfected as indicated for 24 h, after which the expression levels of the indicated proteins were measured by western blotting. The data are presented as the mean +- standard deviation. The experiments were performed at least three times. **P
